Cadila Launches Innovative Tuberculosis Medicine

BMI believes there are three main reasons for India's pharmaceutical sector failing, as yet, to develop a new molecular entity (NME). Its economy has been driven by agriculture rather than heavy industry, the concept of intellectual property has not been embraced and, most importantly, drugmakers have traditionally focused resources on the reverse engineering of patented products. Nevertheless, original pharmaceutical research and development (R&D) is becoming more popular, especially since the introduction of a patent law compliant with the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) in 2005.

To read the full article, please choose one of the following options: